ACOR - Acorda Therapeutics: Buying Before The Coast Is Clear
- Acorda Therapeutics appears to be making moves to prepare for a potential turnaround in the coming years. I intend to discuss the company's prospects for a turnaround.
- The company sold some of their manufacturing operations which provided some cash and decreased INBRIJA's cost of goods. Now, the company has to secure an Ex-U.S. partnership and optimize ARCUS.
- INBIRJA's launch has been lackluster, however, a few adjustments and an end to the pandemic could drastically change its trajectory.
- I reveal my plan for trading Acorda over the next couple of years in anticipation of developing a long-term position.
For further details see:
Acorda Therapeutics: Buying Before The Coast Is Clear